Paper42909255PubMed
Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death.
Levchuk K and 6 others. Front Immunol, 2026.
Cite this record
ConductScience Library. Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death. Papers, record 42909255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42909255
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-24
Source PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chemokines | Major topic |
| Neoplasms | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Animals | |
| Cell Movement | |
| Cell Death | |
| Tumor Microenvironment | |
| Signal Transduction |
Source PubMed
References180
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29311381 | Metabolic Barriers to T Cell Function in Tumors. | J Immunol | 2018 | https://conductscience.org/library/papers/29311381 | PubMed |
| 2 | 28486109 | Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28486109 | PubMed |
| 3 | 34083764 | T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. | Nat Biomed Eng | 2021 | https://conductscience.org/library/papers/34083764 | PubMed |
| 4 | 33262763 | A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. | Front Immunol | 2020 | https://conductscience.org/library/papers/33262763 | PubMed |
| 5 | 37058548 | Metabolic challenges and interventions in CAR T cell therapy. | Sci Immunol | 2023 | https://conductscience.org/library/papers/37058548 | PubMed |
| 6 | 17667919 | Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17667919 | PubMed |
| 7 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 8 | 33020644 | Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. | Nat Med | 2020 | https://conductscience.org/library/papers/33020644 | PubMed |
| 9 | 19847165 | Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. | Nature | 2009 | https://conductscience.org/library/papers/19847165 | PubMed |
| 10 | 37248395 | Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity. | Nat Cancer | 2023 | https://conductscience.org/library/papers/37248395 | PubMed |
| 11 | 39471818 | Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/39471818 | PubMed |
| 12 | 34325726 | IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34325726 | PubMed |
| 13 | 37130030 | Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. | Blood | 2023 | https://conductscience.org/library/papers/37130030 | PubMed |
| 14 | 42250288 | CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. | Int Immunopharmacol | 2026 | https://conductscience.org/library/papers/42250288 | PubMed |
| 15 | 37603742 | The spread of interferon-γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37603742 | PubMed |
| 16 | 37851569 | Functional diversification and dynamics of CAR-T cells in patients with B-ALL. | Cell Rep | 2023 | https://conductscience.org/library/papers/37851569 | PubMed |
| 17 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 18 | 42368560 | Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42368560 | PubMed |
| 19 | 35675405 | Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. | Sci Adv | 2022 | https://conductscience.org/library/papers/35675405 | PubMed |
| 20 | 41533516 | In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment. | Cell Rep | 2026 | https://conductscience.org/library/papers/41533516 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42909255
GET https://conductscience.org/api/papers/v1/42909255/references?page=2